Astragaloside IV-PESV Repressed T Cell Immunosuppression by Inhibiting PD-L1 Expression in Prostate Cancer through STAT3 Pathway

Figure 3

Astragaloside IV-PESV suppressed PD-L1 levels by inhibiting STAT3 signaling to regulate immunity. (a, b) The p-STAT3, STAT3, and PD-L1 expression levels in PC3 cells treated with astragaloside IV-PESV were determined by western blot or IF. vs. Control. (c) Flow cytometry detection of T cell apoptosis. (d) ELISA detection of the expression levels of T cell supernatant IFN-γ, TNF-α, GZMB, and Perforin. vs. Control + T cells. (e) STAT3 level. (f) p-STAT3, STAT3, and PD-L1 levels. (g) ChIP experiments demonstrated that astragaloside IV-PESV inhibited the binding of STAT3 to the PD-L1 promoter. ^& vs. Control.